Physician profile
David Sheyn
NPI 1912131665
$9,985.51
in general payments reported to CMS, 2019-2025
18 companies · $1,284 in 2025
The $1,284 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,763 · 2020: $291 · 2021: $490 · 2022: $1,176 · 2023: $2,581 · 2024: $2,400 · 2025: $1,284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,681 · Travel and Lodging: $1,158 · Honoraria: $333 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,680.79 |
| Travel and Lodging | $1,157.75 |
| Honoraria | $332.63 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $1,899.16 | 2023-2024 | Axonics, Bulkamid |
| Boston Scientific Corporation | $1,501.78 | 2019-2025 | Advantage System, Axonics, General - Female Sui |
| Abbvie INC. | $1,307.54 | 2022-2025 | Botox |
| Medtronic, INC. | $1,251.23 | 2021-2025 | Interstim, Altaviva, Ligasure |
| Bluewind Medical | $1,179.52 | 2024-2025 | Revi |
| Medtronic USA, INC. | $1,093.47 | 2019-2020 | |
| Astellas Pharma US INC | $754.92 | 2019-2025 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $459.55 | 2023-2025 | Gemtesa |
| Allergan, INC. | $251.95 | 2020-2022 | |
| Convatec INC. | $106.13 | 2021-2023 | |
| Abbott Laboratories | $50.65 | 2023-2024 | Proclaim |
| Myovant Sciences INC. | $25.85 | 2022 | |
| 180 Medical, INC. | $23.27 | 2022 | |
| Photocure INC | $18.31 | 2024 | Cysview |
| Pfizer INC. | $17.11 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Palette Life Sciences, INC. | $16.29 | 2023 | |
| Endo Pharmaceuticals INC. | $14.93 | 2022 | |
| Antares Pharma, INC. | $13.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Sheyn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.